What are your top takeaways in Lymphoma from ASH 2025?

1. Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial — This trial may change practice by using the combination of BTK-I and Ven without CD20 antibodies. This time-limited option led to MRD, and I would expe...

1. The EPCORE FL-1 trial randomized patients to R2 vs. epcoritamab-R2. This study indicated that the addition of the CD20/C3 bispecific antibody, epcoritamab, to rituximab and lenalidomide could potentially establish a new standard, given the dramatic improvement in remission duration as compared to th...

Here are my top 3 oral presentations from the 2025 ASH meeting (2 for FL and 1 for DLBCL):

1. Primary results from the EPCORE FL-1 phase 3 study of Epcor + len + R vs R2 in patients with R/R FL: Fixed duration of Epcor + len + R showed 79% reduction in the risk of disease progression and death with high...

1. Phase III clinical trial EPCORE-FL-1 that compared epcoritamab + lenalidomide + rituximab (Epco-R2) vs R2 as second line for R/R follicular lymphoma. The primary endpoint was. With a median follow-up of about 13-14 months, the PFS, DOR, and CR rates were significantly better with Epco-R2 than R2....